Diabetic Macular Edema Clinical Trial
— DMEOfficial title:
A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
Verified date | February 2023 |
Source | Viatris Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Three hundred and twenty-four (324) eligible adult subjects with diabetes mellitus with central DME involvement to be randomized 1:1 to intravitreal treatment with MYL-1701P or Eylea®. The primary endpoint is mean change from baseline in Best Corrected Visual Acuity (BCVA) as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Pharmacokinetics (PK) and immunogenicity to be evaluated in the subjects participating in the study.
Status | Completed |
Enrollment | 355 |
Est. completion date | September 10, 2021 |
Est. primary completion date | November 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female subjects age = 18 years. 2. Subjects have type 1 or type 2 diabetes mellitus who present with central DME involvement in the study eye. 3. The cause of decreased vision in the study eye has been attributed primarily to DME by the Investigator. 4. Subject is able to understand and voluntarily provide written informed consent to participate in the study. 5. If female of child bearing potential, the subject must have a negative serum pregnancy test at the Screening visit and a negative urine pregnancy test at baseline visit, and should not be nursing or planning a pregnancy. 6. If female, subject must be: 1. Surgically sterilized via hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; or 2. Of childbearing potential and practicing an acceptable form of birth control (defined as the use of an intrauterine device; a barrier method, like condom, with spermicide; any form of hormonal contraceptives; or abstinence from sexual intercourse) starting 60 days prior to dosing and continuing at least 90 days following the last treatment. 3. Of non-childbearing potential (i.e., postmenopausal for at least 1 year). 7. If male, subject must be surgically or biologically sterile. If not sterile, the subject must agree to use an acceptable form of birth control with sexual partner (as described in inclusion criteria #6b of protocol) or abstain from sexual relations during the study period and up to 90 days following the last treatment dose. 8. Subject is willing to comply with the study duration, study visits and study related procedures. Exclusion Criteria: 1. Subjects with known hypersensitivity to aflibercept or any of the excipients 2. Subjects with current or planned use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines and ethambutol 3. Subjects with uncontrolled hypertension defined as systolic blood pressure >160mm Hg or diastolic blood pressure > 95 mm of Hg. 4. Subjects with a history of cerebrovascular accident or myocardial infarction within 6 months of randomization. 5. Subjects with history of use of intraocular corticosteroids anytime in the past or periocular (subconjunctival, intra-scleral, sub-tenon or retrobulbar) corticosteroids within 4 months of randomization 6. Subjects who have only one functional eye, even if the eye met all other study requirements, or who have an ocular condition on the fellow eye with a poorer prognosis than the study eye. |
Country | Name | City | State |
---|---|---|---|
Czechia | Mylan Investigator Site | Hradec Králové | |
Czechia | Mylan Investigator Site | Olomouc | |
Czechia | Mylan Investigator Site | Pardubice | |
Czechia | Mylan Investigator Site | Praha 10 | Vinohrady |
Czechia | Mylan Investigator Site | Praha 2 | |
Czechia | Mylan Investigator Site | Praha 5 | |
Czechia | Mylan Investigator Site | Zlín | |
Germany | Mylan Investigator Site | Göttingen | Lower Saxony |
Germany | Mylan Investigator Site | Mainz | Rheinland-Pflaz |
Germany | Mylan Investigator Site | Marburg | |
Hungary | Mylan Investigator Site | Budapest | |
Hungary | Mylan Investigator Site | Budapest | |
Hungary | Mylan Investigator Site | Debrecen | |
Hungary | Mylan Investigator Site | Nyíregyháza | |
Hungary | Mylan Investigator Site | Pecs | |
Hungary | Mylan Investigator Site | Szeged | |
Hungary | Mylan Investigator Site | Zalaegerszeg | |
India | Mylan Investigator Site | Ahmedabad | Gujarat |
India | Mylan Investigator Site | Ahmedabad | Gujarat |
India | Mylan Investigator Site | Bangalore | Karnataka |
India | Mylan Investigator site | Bangalore | Karnataka |
India | Mylan Investigator Site | Bangalore | Karnataka |
India | Mylan Investigator Site | Bhubaneswar | Orissa |
India | Mylan Investigator Site | Chandigarh | Punjab |
India | Mylan Investigator Site | Hyderabad | Telangana |
India | Mylan Investigator Site | Jaipur | Rajasthan |
India | Mylan Investigator Site | Madurai | Tamilnadu |
India | Mylan Investigator Site | Mumbai | Maharashtra |
India | Mylan Investigator Site | New Delhi | Delhi |
India | Mylan Investigator Site | Noida | Uttar Pradesh |
India | Mylan Investigator Site | Tirunelveli | Tamilnadu |
India | Mylan Investigator Site | Visakhapatnam | Andhra Pradesh |
Japan | Mylan Investigator Site | Fukuoka | |
Japan | Mylan Investigator Site | Fukushima | |
Japan | Mylan Investigator Site | Kagoshima | |
Japan | Mylan Investigator Site | Kofu | Yamanashi |
Japan | Mylan Investigator Site | Koriyama | Fukushima |
Japan | Mylan Investigator Site | Kumamoto | |
Japan | Mylan Investigator Site | Mito | Ibaraki |
Japan | Mylan Investigator Site | Nagasaki | |
Japan | Mylan Investigator Site | Nagoya | Aichi |
Japan | National Hospital Organization Osaka National Hospital | Osaka | |
Japan | Mylan Investigator Site | Saitama | |
Japan | Mylan Investigator Site | Sapporo | Hokkaido |
Japan | Mylan Investigator Site | Susono | Shizuoka |
Japan | Mylan Investigator Site | Yamato | Kanagawa |
Latvia | Mylan Investigator Site | Jelgava | |
Latvia | Mylan Investigator Site | Riga | |
Latvia | Mylan Investigator Site | Riga | |
Poland | Mylan Investigator Site | Katowice | Slaskie |
Poland | Mylan Investigator Site | Lódz | Lodzkie |
Poland | Mylan Investigator Site | Olsztyn | Warminsko-Mazurskie |
Poland | Mylan Investigator Site | Rzeszów | |
Poland | Mylan Investigator Site | Tarnów | Tarnow |
Poland | Mylan Investigator Site | Walbrzych | |
Russian Federation | Mylan Investigator Site | Kazan | Tatarstan Resp. |
Russian Federation | Mylan Investigator Site | Moscow | |
Russian Federation | Mylan Investigator Site | Novosibirsk | |
Russian Federation | Mylan Investigator Site | Omsk | |
Russian Federation | Mylan Investigator Site | Saint Petersburg | |
United States | Mylan Investigator Site | Abilene | Texas |
United States | Mylan Investigator Site | Augusta | Georgia |
United States | Mylan Investigator Site | Chevy Chase | Maryland |
United States | Mylan Investigator Site | Ladson | South Carolina |
United States | Mylan Investigator Site | Morgantown | West Virginia |
United States | Mylan Investigator Site | Nashville | Tennessee |
United States | Mylan Investigator Site | Paducah | Kentucky |
United States | Mylan Investigator Site | Phoenix | Arizona |
United States | Mylan Investigator Site | Phoenix | Arizona |
United States | Mylan Investigator Site | Sacramento | California |
United States | Mylan Investigator Site | Saint Petersburg | Florida |
United States | Mylan Investigator Site | Shawnee Mission | Kansas |
United States | Mylan Investigator Site | Winter Haven | Florida |
Lead Sponsor | Collaborator |
---|---|
Mylan Pharmaceuticals Inc | Momenta Pharmaceuticals, Inc. |
United States, Czechia, Germany, Hungary, India, Japan, Latvia, Poland, Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 8 | Mean change from baseline in BCVA as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) letters at week 8.
Best Corrected Visual Acuity (BCVA) is measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the ETDRS chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. |
Baseline and 8 weeks | |
Secondary | The Mean Change From Baseline in Central Retinal Thickness (CRT) | The mean change from baseline in Central Retinal Thickness as determined by Spectral domain- Optical coherence tomography (SD-OCT) over time | From baseline to week 52 | |
Secondary | The Mean Change in BCVA | Mean change from baseline in BCVA as assessed by ETDRS letters over time. Best Corrected Visual Acuity (BCVA) is measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the ETDRS chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening | From baseline to week 52 | |
Secondary | Number of Subjects Who Gained =15 Letters From Baseline in BCVA | Number of subjects who gained =15 letters from baseline in BCVA, assessed in change from baseline in ETDRS letters over time | From baseline to week 52 | |
Secondary | Number of Administrations of Study Drug Required | The mean number of doses administered during the 52 weeks of study | From baseline to week 52 | |
Secondary | Number of Participants With Treatment Emergent Adverse Events | Number of Participants with Treatment Emergent Adverse Events (Safety and tolerability) | From baseline to week 52 | |
Secondary | Number of Subjects With Induced and Boosted Anti-Drug Antibodies | Number of subjects with induced and boosted Anti-Drug Antibodies (ADA) (Immunogenicity) | From baseline to week 52 | |
Secondary | Concentration of Aflibercept in Blood (Pharmacokinetics) | Free Drug Concentration of aflibercept in blood (Pharmacokinetics) | 2 Days after Week 16 Injection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03953807 -
A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated
|
Phase 4 | |
Completed |
NCT03622580 -
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
|
Phase 3 | |
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Terminated |
NCT04603937 -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Terminated |
NCT04611152 -
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Active, not recruiting |
NCT04108156 -
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab
|
Phase 3 | |
Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
Withdrawn |
NCT03629210 -
Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema
|
Phase 2 | |
Withdrawn |
NCT02842541 -
Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema
|
Phase 1 | |
Completed |
NCT02221453 -
Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide
|
Phase 2 | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Completed |
NCT02979665 -
Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
|
||
Completed |
NCT02000102 -
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
|
N/A | |
Completed |
NCT02088229 -
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
|
N/A | |
Terminated |
NCT00779142 -
Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies
|
N/A | |
Completed |
NCT01171976 -
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT00989989 -
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
|
Phase 3 | |
Completed |
NCT01259609 -
Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy
|
N/A | |
Completed |
NCT00683176 -
Effect of Choline Fenofibrate (SLV348) on Macular Edema
|
Phase 2 | |
Terminated |
NCT00768040 -
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
|
Phase 2 |